Bank of America’s Liminatus Pharma LIMN Stock Holding History

Bank of America’s Portfolio LIMN Stock Details LIMN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1	Closed	-$27	–	7200
2025 Q4	$27	Hold	1	–	–	﹤0.01%	7078
2025 Q3	$113	Hold	1	–	–	﹤0.01%	7833
2025 Q2	$735	Buy	+1	New	+$561	﹤0.01%	7588

Other funds holding LIMN

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

CCA

Cygnus Capital Advisors Atlanta, Georgia $147M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Personalized Indexing Management Oakland, California $12.2B AUM 47.93% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

TSS

Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

Bank of America's LIMN Position: Q1 2026 in Review

Bank of America sold out of Liminatus Pharma (LIMN) in Q1 2026, closing a stake of 1 share — an estimated $27 sold.

Bank of America first reported a position in LIMN in Q2 2025 and held it in 3 quarters. The position peaked at $735 in Q2 2025. 14 funds tracked by Wall St. Rank hold LIMN as of Q1 2026.

Bank of America reported no remaining Liminatus Pharma position as of Q1 2026 after selling out during the quarter.
Bank of America sold 1 Liminatus Pharma share in Q1 2026, an estimated $27.
Bank of America first reported a position in Liminatus Pharma in Q2 2025 and held it in 3 quarters.
Bank of America's Liminatus Pharma position peaked at $735 in Q2 2025.
14 funds tracked by Wall St. Rank held Liminatus Pharma as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.